Skip to main content
. 2022 Jul 11;12(7):e063456. doi: 10.1136/bmjopen-2022-063456

Figure 1.

Figure 1

Malaria genomic use cases and National Malaria Control Programme (NMCP) decisions. The letter on the left (A–D) expresses the level of action described in the WHO Technical consultation on the role of parasite and anopheline genetics in malaria surveillance. (A) Immediate action; (B) medium-term action; (C) long-term action. Arrows in colour at the right express the research required for action in the medium-term and long-term (grey, not essential for action; green, immediate evidence; yellow, medium-term evidence). ANC, antenatal care clinics; IPT, intermittent preventive treatment; MDA, mass drug administration; rfMDA, reactive focal MDA; SMC, seasonal malaria chemoprevention.